In vivo models have been the drug safety standard for as long as there have been drug safety standards. With mounting data proving the worth of in vitro models, could there be a future where we will not need in vivo? I am joined by Anjli Venkateswaran, Director of Strategic Partnerships for Charles River, to discuss this trending topic.